Lecture
Covid-19: what will it take to vaccinate the world?
- High-income nations are expected to secure approximately 60% of 2 billion pre-ordered AstraZeneca doses, all Moderna supply, and nearly 75% of Pfizer doses, potentially necessitating donations of surplus stock based on political will.
- AstraZeneca is anticipated to be the most widely used global vaccine due to its low cost, high volume, and distributed manufacturing, though delivery logistics remain a significant challenge for many poorer nations and India specifically.
- Israel is positioned to lead the Pfizer rollout through a data-sharing agreement, while India faces potential cold-chain constraints despite refrigeration requirements.
- Roughly 3% of each country's population may receive adequate vaccine supplies by summer via the COVAX scheme, leaving a large global shortfall that may drive nations toward Chinese and Russian alternatives.
- Skepticism surrounds the transparency of Chinese and Russian vaccines, with concerns that Sinopharm trial data from the UAE may remain unpublished and that Sputnik V may have compromised safety standards, potentially damaging Russia's reputation.
- China's vaccine diplomacy in the Middle East is viewed as potentially politically motivated, with the efficacy of these jabs uncertain pending the release of underlying data.
- Distributing vaccines according to global need rather than national wealth is predicted to save 1.5 times more lives compared to current concentrated models.
- Successful vaccine rollout is projected to enable greater international collaboration on issues like climate change, whereas a fractious response could hinder progress on other global challenges.